Physician profile
Guobin Wang
NPI 1871850503
$5,692.51
in general payments reported to CMS, 2019-2025
25 companies · $1,458 in 2025
The $1,458 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $790 · 2022: $1,270 · 2023: $802 · 2024: $1,373 · 2025: $1,458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,368 · Education: $265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,367.65 |
| Education | $264.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,191.85 | 2021-2025 | Tremfya |
| Abbvie INC. | $883.71 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $667.97 | 2021-2025 | |
| Lilly USA, LLC | $506.16 | 2021-2024 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $403.97 | 2021-2024 | |
| Dermavant Sciences, INC. | $311.64 | 2023-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $280.32 | 2023-2024 | Sotyktu |
| Amgen INC. | $223.73 | 2021-2025 | Otezla, Otezla |
| Incyte Corporation | $209.45 | 2025 | Opzelura, Opzelura |
| Organon LLC | $159.46 | 2025 | Vtama |
| Genzyme Corporation | $140.98 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $125.00 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $110.77 | 2021-2022 | |
| Ucb, INC. | $102.35 | 2022-2024 | Bimzelx, Cimzia |
| Leo Pharma INC. | $65.31 | 2023-2025 | Anzupgo, Adbry |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Botanix Sb INC | $50.18 | 2025 | Sofdra |
| Fresenius Kabi USA, LLC | $46.37 | 2023 | Idacio |
| Arcutis Biotherapeutics, INC. | $45.10 | 2024-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $43.89 | 2022-2025 | |
| Dermira, INC. | $39.75 | 2021 | |
| Almirall LLC | $18.50 | 2025 | Seysara |
| Krystal Biotech INC | $18.45 | 2023 | Vyjuvek |
| Paratek Pharmaceuticals, INC. | $18.08 | 2024 | Nuzyra |
| Strata Skin Sciences, INC. | $17.08 | 2024 | Xtrac |
| Phadia US INC. | $12.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guobin Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.